CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program

Myoung Kyun Son, Min-Hee Ryu, Joon Oh Park, Seock-Ah Im, Tae-Yong Kim, Su Jin Lee, Baek-Yeol Ryoo, Sook Ryun Park, Yoon-Koo Kang

Cancer Research and Treatment. 2017;49(2):350-357. Published online 2016 July 19 DOI: https://doi.org/10.4143/crt.2016.067

Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program

Myoung Kyun Son, Min-Hee Ryu, Joon Oh Park, Seock-Ah Im, Tae-Yong Kim, Su Jin Lee, Baek-Yeol Ryoo, Sook Ryun Park, Yoon-Koo Kang

Cancer Research and Treatment. 2017;49(2):350-357

Link1 Link2

Link3

Regorafenib: A Guide to Its Use in Advanced Gastrointestinal Stromal Tumor (GIST) After Failure of Imatinib and Sunitinib

Katherine A. Lyseng-Williamson

BioDrugs. 2013;27(5):525-531

Link1

Link2 Link3

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

P.J. Loehrer

Yearbook of Oncology. 2008;2008:303-305

Link1 Link2

Efficacy and safety of apatinib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial

Z. Cai, B. Zhang, Y. Yin, D. Cao

Annals of Oncology. 2019;30:v698

Link1 Link2 Link3

The efficacy and adverse events of regorafenib in advanced gastrointestinal stromal tumors after imatinib and sunitinib failure: a systemic review and meta-analysis

xue zhang, Ai-Li Zhang, Jiao Zhang, Hong-Ying Xia, Xi Gu, Li-Juan Ding, Xiaoxiao Zhang, Wenjie Yin

. 2023;

Link1 Link2

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib

Akira Sawaki, Tatsuo Kanda, Yoshito Komatsu, Toshirou Nishida

Gastroenterology Research and Practice. 2014;2014:1-6

Link1

Link2 Link3

Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo

Chris D. Poole, Mark P. Connolly, Jane Chang, Craig J. Currie

Gastric Cancer. 2014;18(3):627-634

Link1

Link2 Link3

Sunitinib—a new approach following failure of imatinib in patients with advanced gastrointestinal stromal tumor

Maria Debiec-Rychter

Nature Clinical Practice Oncology. 2007;4(6):342-343

Link1

Link2 Link3

Phase II study of paclitaxel in patients with advanced gastrointestinal stromal tumor (GIST) after failure of at least both imatinib and sunitinib

H. Cho, M.-H. Ryu, B.J. Kim, Y. Park, Y.-S. Na, J. Ma, M.Y. Beck, Y.-K. Kang

Annals of Oncology. 2018;29:viii583

Link1 Link2 Link3

Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib

Jae-Joon Kim, Min-Hee Ryu, Changhoon Yoo, Mo Youl Beck, Jung Eun Ma, Yoon-Koo Kang

The Oncologist. 2019;24(11):e1212-e1218

Link1 Link2 Link3

Link4

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.